CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

BACKGROUND: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8(+) T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8(+) T-cell epitopes can driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Minglu, Xie, Luoyingzi, Cao, Guoshuai, Lei, Shun, Wang, Pengcheng, Wei, Zhengping, Luo, Yuan, Fang, Jingyi, Yang, Xingxing, Huang, Qizhao, Xu, Lifan, Guo, Junyi, Wen, Shuqiong, Wang, Zhiming, Wu, Qing, Tang, Jianfang, Wang, Lisha, Chen, Xiangyu, Chen, Cheng, Zhang, Yanyan, Yao, Wei, Ye, Jianqiang, He, Ran, Huang, Jun, Ye, Lilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114852/
https://www.ncbi.nlm.nih.gov/pubmed/35580929
http://dx.doi.org/10.1136/jitc-2021-004022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114852/
https://www.ncbi.nlm.nih.gov/pubmed/35580929
http://dx.doi.org/10.1136/jitc-2021-004022

Ejemplares similares